US 12,258,413 B2
Bispecific antibody binding to TfR
Keisuke Mitamura, Tokyo (JP); Ryosuke Nakano, Tokyo (JP); Masayuki Kai, Tokyo (JP); and Nobuaki Takahashi, Tokyo (JP)
Assigned to KYOWA KIRIN CO., LTD., Tokyo (JP)
Appl. No. 17/418,447
Filed by Kyowa Kirin Co., Ltd., Tokyo (JP)
PCT Filed Dec. 27, 2019, PCT No. PCT/JP2019/051594
§ 371(c)(1), (2) Date Jun. 25, 2021,
PCT Pub. No. WO2020/138487, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. 2018-248334 (JP), filed on Dec. 28, 2018.
Prior Publication US 2022/0017635 A1, Jan. 20, 2022
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/2881 (2013.01) [A61P 35/00 (2018.01); C07K 16/2863 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/92 (2013.01)] 10 Claims
 
1. A bispecific antibody or a bispecific antibody fragment thereof, comprising:
an IgG portion that binds to a transferrin receptor (TfR) and an N-terminal side polypeptide that binds to a cell surface antigen,
wherein the IgG portion includes VH having CDRs 1 to 3 containing the amino acid sequences represented by SEQ ID NOs: 32 to 34, respectively, and VL having CDRs 1 to 3 containing the amino acid sequences represented by SEQ ID NOs: 17 to 19, respectively,
wherein the N-terminal side polypeptide is Fab of an antibody against EGFR, and the antibody includes VH having CDRs 1 to 3 containing the amino acid sequences represented by SEQ ID NOs: 65 to 67, respectively, and VL having CDRs 1 to 3 containing the amino acid sequences represented by SEQ ID NOs: 17 to 19, respectively,
wherein the bispecific antibody or the bispecific antibody fragment thereof binds to TfR and the cell surface antigen,
wherein the N-terminal side polypeptide binds directly or through a linker to the N terminus of a heavy chain of the IgG portion.